Ironwood Pharmaceuticals, Inc. - (IRWD): Price and Financial Metrics
IRWD Price/Volume Stats
|Current price||$10.30||52-week high||$12.66|
|Prev. close||$9.90||52-week low||$8.07|
|Day high||$10.35||Avg. volume||2,289,414|
|50-day MA||$9.46||Dividend yield||N/A|
|200-day MA||$10.19||Market Cap||1.61B|
IRWD Stock Price Chart Interactive Chart >
IRWD POWR Grades
- IRWD scores best on the Quality dimension, with a Quality rank ahead of 92.13% of US stocks.
- The strongest trend for IRWD is in Value, which has been heading down over the past 177 days.
- IRWD ranks lowest in Sentiment; there it ranks in the 12th percentile.
IRWD Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IRWD is -1.34 -- better than merely 5.1% of US stocks.
- Of note is the ratio of IRONWOOD PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; just 3.59% of US stocks have a lower such ratio.
- Over the past twelve months, IRWD has reported earnings growth of -470.19%, putting it ahead of merely 3.16% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to IRONWOOD PHARMACEUTICALS INC, a group of peers worth examining would be KOS, CHK, JRVR, EQT, and SM.
- Visit IRWD's SEC page to see the company's official filings. To visit the company's web site, go to www.ironwoodpharma.com.
IRWD Valuation Summary
- In comparison to the median Healthcare stock, IRWD's price/earnings ratio is 106.58% lower, now standing at -1.6.
- Over the past 167 months, IRWD's EV/EBIT ratio has gone up 11.8.
Below are key valuation metrics over time for IRWD.
IRWD Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 72.77%.
- The 5 year price growth rate now stands at -33.93%.
- Its 3 year cash and equivalents growth rate is now at 394.3%.
The table below shows IRWD's growth in key financial areas (numbers in millions of US dollars).
|Date||Revenue||Operating Cash Flow||Net Income to Common Stock|
IRWD's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- IRWD has a Quality Grade of B, ranking ahead of 94.53% of graded US stocks.
- IRWD's asset turnover comes in at 0.622 -- ranking 50th of 682 Pharmaceutical Products stocks.
- LGND, COLL, and OMER are the stocks whose asset turnover ratios are most correlated with IRWD.
The table below shows IRWD's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
Ironwood Pharmaceuticals, Inc. - (IRWD) Company Bio
Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.
IRWD Latest News Stream
|Loading, please wait...|
IRWD Latest Social Stream
View Full IRWD Social Stream
Latest IRWD News From Around the Web
Below are the latest news stories about IRONWOOD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
BOSTON, November 21, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript November 9, 2023 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.09 EPS, expectations were $0.17. Operator: Thank you for standing by. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone […]
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
Q3 2023 Ironwood Pharmaceuticals Inc Earnings Call
Ironwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year Guidance
Third Quarter 2023 Financial Results and Business Highlights
IRWD Price Returns
Continue Researching IRWDHere are a few links from around the web to help you further your research on Ironwood Pharmaceuticals Inc's stock as an investment opportunity:
Ironwood Pharmaceuticals Inc (IRWD) Stock Price | Nasdaq
Ironwood Pharmaceuticals Inc (IRWD) Stock Quote, History and News - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Stock Price and Basic Information | MarketWatch